Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.

Chinese medical journal - 1 Jan 2013

Chen Guang-cheng, Yu Tao, Min Xiao-hui, Zhao Li-na, Qing Qing, Yuan Yu-hong, Su Hong, Zhan Jun, Huang Kai-hong, Chen Qi-kui

Abstract excerpt

BACKGROUND: The long-term effectiveness and safety of lamivudine in patients with decompensated hepatitis B virus-related cirrhosis are still not clear. The present study attempted to describe the clinical outcomes of lamivudine therapy in these special patients over three years. METHODS: This study was a retrospective, controlled cohort study which involved 153 patients with decompensated hepatitis B...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Hepatitis B

Share to Hepatitis B virus

Share to Lamivudine

Share to Liver Cirrhosis

Share to Prognosis

Source

Identifiers

PMID: 23595391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.PMID 23595391Read ↗

Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.Semantic proximity Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.Semantic proximity Read ↗

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.Semantic proximity Read ↗

Lamivudine for patients with chronic hepatitis B and advanced liver disease.Semantic proximity Read ↗

Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.Semantic proximity Read ↗

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.Semantic proximity Read ↗

HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.Semantic proximity Read ↗

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.